Effect-site concentration of propofol required for LMA-Supreme™ insertion with and without remifentanil: a randomized controlled trial

BMC Anesthesiology

Research Article

Maite López-Gil¹  Salomé Agustí²  Consuelo Jiménez²  Emilia Bastida²  Maite Portas²  Matilde Zaballos³ 

[1] Department of Anaesthesia, Head Department of Anaesthesiology, Hospital Universitario Gregorio Marañón, Madrid, Spain;Department of Anaesthesiology, Hospital Universitario Gregorio Marañón, Madrid, Spain;Department of Toxicology, Faculty of Medicine, Complutense University, Madrid, Spain;Department of Anaesthesiology, Hospital Universitario Gregorio Marañón, Madrid, Spain;

关键词: Anaesthetics;    Intravenous;    Propofol;    Remifentanil;    Equipment;    Laryngeal mask airway supreme;   

DOI  :  10.1186/s12871-015-0115-8

 received in 2014-12-01, accepted in 2015-09-24,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundA new supraglottic device, the LMA-Supreme™, has recently become available for clinical use. Information on anaesthetic and co-adjuvant requirements for insertion of the LMA-Supreme™ is limited. The present study aimed to evaluate the optimal effect-site concentration of propofol in 50 % (EC50) of adults necessary for successful insertion of the LMA-Supreme™ and to examine remifentanil’s effect on propofol requirements.MethodsFifty-eight elective patients (aged 18–60 years; ASA (American Society Anaesthesiologists) physical status classification I and II) scheduled for day surgery were randomly assigned to one of two groups: propofol with saline or propofol with remifentanil. Anaesthesia was induced by target-controlled infusion according to predetermined effect-site concentrations of propofol and remifentanil (5 ng.mL−1). The EC50 was calculated using Dixon’s up-and-down method. Ten minutes following drug administration, LMA-Supreme™ insertion was attempted without the use of muscle relaxant drugs.ResultsIn the propofol + saline group, the EC50 of propofol required for LMA-Supreme™ insertion was 6.32 ± 0.67 μg.mL−1 (95 % CI, 5.69–6.94 μg.mL−1). With the addition of remifentanil at an effect-site concentration of 5 ng.mL−1, the EC50 of propofol required for LMA-Supreme™ insertion was 2.50 ± 0.80 μg.mL−1 (95 % CI, 1.82–3.17 μg.mL−1; p < 0.0001).ConclusionsThe propofol requirement for smooth insertion of the LMA-Supreme™ was 60 % less when remifentanil (5 ng.mL−1) was co-administered.Clinical trial registrationIdentified as NCT01974648 at www.clinicaltrials.gov.

【 授权许可】

CC BY   
© Zaballos et al. 2015